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ReportsHigh Prevalence of Untreated
Depression in Patients Accessing
Low-Vision ServicesNews about untreatable sight loss is devastating. Clinicians have an
important role to play in determining when and how information is
provided, gauging how effectively patients are likely to cope, and
recognizing when someone needs to access treatment for their
psychological distress. It is true that some resilient individuals are
able to adjust, eventually, to their new situation, but many others
ﬁnd the myriad of practical problems associated with sight loss and
worry about the future overwhelming, their psychological well-
being suffers, and many sink into chronic depression. Depression
is common in those with a visual impairment and particularly so in
those seeking help at low vision rehabilitation clinics, but just how
prevalent is it and are people getting the help they need?
Large-scale epidemiologic studies indicate that about 13% of
people with a visual impairment have signiﬁcant depressive symp-
toms, about 3 times greater than in the general population.1 In those
accessing low vision rehabilitation clinics the prevalence is known
to be higher at about 30%.2 However, these estimates should be
treated with caution. Small sample sizes and volunteers rather than
consecutive attendees may underestimate the scale of the problem
because people with depression are less likely to volunteer. The
data in this report are from the Depression in Visual Impairment
Trial (DEPVIT), a multicenter, randomized controlled trial that
screened >1000 consecutive attendees at low vision rehabilitation
clinics in Britain (ISRCTN46824140).3 Two important aims of the
study were to estimate the prevalence of signiﬁcant depressive
symptoms in consecutive attendees at National Health Service
(NHS) funded low vision rehabilitation services in Britain and to
identify the proportion currently accessing treatments for depression.
Participants were consecutive adult patients attending 1 of 16 low
vision rehabilitation services in Britain between November 2011 and
March 2014. Fourteen of the services were provided in a primary care
setting in Wales and the others were hospital-based services in
London. All of the clinics gave a routine preassessment survey to all
patients before their clinic visit. The survey included the Geriatric
Depression Scale (GDS-15) to quantify depressive symptoms, a short
version of the National Eye Institute Visual Function Questionnaire
(7-item NEI-VFQ) and a single question from the Short Form Health
Survey to assess overall health. To ensure that data collection was
standardized across centers, clinicians attended a 1-day training event
to improve their understanding of depression and all study pro-
cedures. For those who consented, information on date of birth,
gender, ethnicity, medical illness, time since vision loss ﬁrst identi-
ﬁed, primary ocular diagnosis, corrected Early Treatment Diabetic
Retinopathy Study logarithm of the minimum angle of resolution
acuity and threshold reading ability (Bailey-Lovie Word Reading
Chart) was recorded at the clinic. In line with the large-scale Medical
Research Council assessment of older adults study, we adopted the
relatively conservative cutoff score of 6 on the GDS-15 to identify
those with signiﬁcant depressive symptoms.1 People who screened
positive for depressive symptoms were also asked if they were
receiving treatment for their low mood.Data were analyzed on STATA Ver 12. The prevalence of
depressive symptoms together with 95% CIs was computed by the
exact binomial method. Ethical approval was obtained from the
NHS National Research Ethics Service (11/WA/0014).
During the 30-month recruitment period, a total of 1323
consecutive adult patients attended the low vision rehabilitation
clinics. Of these, consenting patients 1008 (76.2%) provided
complete datasets. The mean (SD) age of consenting patients was
74.4 (16.1) years, 61.7% were women, and 52.8% had a diagnosis
of age-related macular degeneration. Overall, the prevalence of
signiﬁcant depressive symptoms, as measured by a GDS-15 score
of6, was 43% (95% CI, 40%e46%). And, of those who screened
positive for signiﬁcant depressive symptoms, 74.8% (95% CI,
79.2%e70.7%) were not being treated for their depression. Table 1
(available at www.aaojournal.org) describes the prevalence of
signiﬁcant depressive symptoms according to study location and
patient characteristics. Interestingly, a regression analysis
indicated that the prevalence of signiﬁcant depressive symptoms
was not related to visual acuity or to the time since sight loss
was ﬁrst identiﬁed. Figure 1 describes the prevalence of
signiﬁcant depressive symptoms as a function of time since the
onset of sight loss and it seems that depression does not resolve
over time. However, because this was a cross-sectional study, we
cannot rule out the possible effects of time.
The prevalence of clinically signiﬁcant depressive symptoms in
43% of those seeking help for sight loss in Britain is striking. To
put the ﬁndings into perspective, 45% of those with a diagnosis of
cancer who are about to undergo chemotherapy have clinically
signiﬁcant depressive features.4 Clearly, people seeking help for
their visual problems are a high-risk group for depression, but
the fact that three-quarters of those who screened positive were not
receiving any form of treatment suggests that depression is being
routinely overlooked in this vulnerable group. We are only aware
of 2 low vision services in Britain that screen people regularly for
depression. People are not getting the help they need.
Addressing a patient’s needs should include more than
improving their acuity or other aspect of visual function. Depres-
sion is a major cause of disability in its own right; it reduces the
effectiveness of low vision rehabilitation interventions, quality of
life, and even life expectancy. Depression is a medical condition,
treatments can be effective, and screening is relatively straight-
forward. In Britain, the National Institute for Health and Clinical
Excellence (NICE) recommend screening high risk groups by
asking a few simple questions which are provided in Table 2
(available at www.aaojournal.org).5 Alternatively, questionnaires
such as the GDS-15 or PHQ-9 are excellent screeners that can be
administered in <5 minutes.
Clinicians providing rehabilitation services want to improve the
lives of their patients. We suggest that the introduction of
depression screening and referral for treatment where appropriate
may be a useful step forward.
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Figure 1. Prevalence of depression as a function of time since sight loss
based on data from 1008 people screened. Error bars describe the 95%
conﬁdence interval (CI). The thick horizontal line describes the overall
prevalence ﬁgure of 43%.
Ophthalmology Volume -, Number -, Month 2015
2ROBIN J. CASTEN, PHD4
RHIANNON T. EDWARDS, PHD2
MARK T. HEGEL, PHD5
SARAH JANIKOUN, MD6
SANDRA E. JUMBE, MSC7
BARBARA RYAN, PHD1
JULIA SHEARN, MPHIL8
DANIEL J. SMITH, MD9
MILES STANFORD, MD6
WEN XING, MSC3
TOM H. MARGRAIN, PHD1
1School of Optometry and Vision Sciences, Cardiff University, Cardiff,
UK; 2Centre for Health Economics and Medicines Evaluation, School
of Healthcare Sciences, Bangor University, Gwynedd, UK; 3NIHR BRC
for Ophthalmology at Moorﬁelds Eye Hospital NHS Foundation Trust
and UCL Institute of Ophthalmology, London, UK; 4Department of
Psychiatry and Human Behaviour, Sidney Kimmel Medical College at
Thomas Jefferson University, Jefferson Hospital for Neuroscience,
Philadelphia, Pennsylvania; 5Department of Psychiatry, Geisel School
of Medicine at Dartmouth, Hanover, New Hampshire; 6Ophthalmology
(Eye) Department South Wing, St Thomas’ Hospital, London, UK;
7NISCHR CRC South East Wales Research Network / RhwydwaithYmchwil De Ddwyrain Cymru, Cardiff, UK; 8Faculty of Life Sciences
and Education, Glyntaff Campus, University of South Wales,
Pontypridd, Wales, UK; 9Institute of Health and Wellbeing, University
of Glasgow, Mental Health and Wellbeing Research Group, Gartnavel
Royal Hospital, Scotland, UK
Financial Disclosure(s): The authors have no proprietary or commercial
interest in any materials discussed in this article.
Supported by Guide Dogs (grant no. OR-2009 07b). The sponsor or
funding organization had no role in the design or conduct of this
research.
Author Contributions:
Conception and design: Nollett, Bray, Bunce, Casten, Edwards, Hegel,
Ryan, Shearn, Smith, Stanford, Margrain
Analysis and interpretation: Nollett, Bray, Bunce, Smith, Xing,
Margrain
Data collection: Nollett, Hegel, Janikoun, Jumbe, Ryan, Shearn,
Stanford, Xing, Margrain
Overall responsibility: Nollett, Bray, Bunce, Casten, Edwards, Hegel,
Janikoun, Jumbe, Ryan, Shearn, Smith, Stanford, Xing, Margrain
Correspondence:
Tom H. Margrain, PhD, School of Optometry and Vision Sciences,
Cardiff University, CF 24 4LU, UK. E-mail: margrainth@cardiff.ac.uk.References
1. Evans JR, Fletcher AE, Wormald RPL. Depression and anxiety
in visually impaired older people. Ophthalmology 2007;114:
283–8.
2. Horowitz A, Reinhardt JP, Boerner K. The effect of rehabili-
tation on depression among visually disabled older adults.
Aging Ment Health 2005;9:563–70.
3. Margrain TH, Nollett C, Shearn J, et al. The Depression in
Visual Impairment Trial (DEPVIT): trial design and protocol.
BMC Psychiatry [serial online] 2012;12:57. Available at,
www.biomedcentral.com/1471-244X/12/57. Accessed June 1,
2015.
4. Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening
older cancer patients: ﬁrst evaluation of the G-8 geriatric
screening tool. Ann Oncol 2012;23:2166–72.
5. National Institute for Health and Clinical Excellence. Depres-
sion in adults with a chronic physical health problem:
treatment and management. NICE 2009:CG91. Available at,
www.nice.org.uk/guidance/cg91/resources/guidance-depression-
in-adults-with-a-chronic-physical-health-problem-pdf. Accessed
June 1, 2015.
